BioCentury | Nov 1, 2012
Distillery Therapeutics

Indication: Neurology

...Licensing status Publication and contact information Neurology Encephalopathy Potassium channel subfamily T member 1 (KCNT1) Genetic studies suggest activating mutations in KCNT1...
...seizures of infancy (MMPSI). Exome sequencing studies of 12 patients with MMPSI, identified mutations in KCNT1...
...rat Kcnt1 with the disease-associated mutations was a constitutively active ion channel, whereas wild-type rat Kcnt1...
BioCentury | Mar 31, 2011
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Epilepsy Potassium channel subfamily V member 2 (KCNV2; Kv8.2) Human genetic and mouse studies suggest that mutations in the KCNV2 gene...
BioCentury | Apr 29, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Depression Potassium channel, subfamily K, member 2 (KCNK2; TREK-1) In vitro and mouse studies suggested that inhibiting TREK-1 with the spadin peptide could help...
BioCentury | Apr 29, 2010
Targets & Mechanisms

TREK-ing after a new antidepressant

French researchers have developed a peptide inhibitor of TREK-1 that they think produces antidepressant effects much faster than marketed selective serotonin reuptake inhibitors. 1 NeuroSearch A/S is now considering moving into lead optimization with an...
Items per page:
1 - 4 of 4